AMENDMENTS TO THE CLAIMS

1-23. (Previously cancelled)

24. (Currently amended) A pharmaceutical composition for use in breast cancer therapy in humans, said composition comprising:

(a) an antineoplastic agent and a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, or combination thereof, and

(b) an aromatase inhibitor and a pharmaceutically acceptable carrier, pharmaceutically acceptable diluent, or combination thereof,

wherein said antineoplastic agent and said aromatase inhibitor are present in superadditive antitumor effective amounts,

~~and further wherein the aromatase inhibitor is not aminogluthetimide, when the antineoplastic agent is a combination consisting of cyclophosphamide, doxorubicin and 5-fluorouracyl~~

and wherein the antineoplastic agent is selected from the group consisting of doxorubicin, epirubicin, idarubicin, nemorubicin, mitoxantrone, losoxantrone, etoposide, teniposide, paclitaxel, docetaxel, vinblastine, vinorelbine, cyclophosphamide, ifosfamide, melphalan, 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulfonyldaunorubicin, fluorouracil, capecitabine, gemcitabine, methotrexate, edatrexate, topotecan, irinotecan, 9-nitrocamptothecin and a polymeric derivative of camptothecin designated PNU 166148, and the aromatase inhibitor is selected from the group consisting of exemestane, formestane, fadrozole, vorozole, letrozole, anastrozole and 4-[(4-bromobenzyl)(4-cyanophenyl)amino]-4H-1,2,4-triazole.

25. (Currently canceled)

26. (Currently canceled)

27. (Currently canceled)

28. (Currently amended) The pharmaceutical composition according to claim ~~26~~ 24, wherein said pharmaceutical composition comprises 1 , 2 or 3 antineoplastic agents selected from the group consisting of epirubicin, doxorubicin, idarubicin, paclitaxel, docetaxel, 5-fluorouracil, cyclophosphamide and vinorelbine, and 1 or 2 steroidal aromatase inhibitors selected from the group consisting of exemestane, formestane, anastrozole, letrozole and fadrozole.

29. (Currently canceled).

30. (Previously presented) The pharmaceutical composition according to Claim 28, wherein the composition comprises one or two antineoplastic agents selected from the group consisting of epirubicin and docetaxel, and the steroidal aromatase inhibitor is exemestane.

31. (Previously presented) The pharmaceutical composition, according to Claim 24, wherein:

- an effective antineoplastic amount of vinblastine is from about 3 mg/m^2 to about 10 mg/m^2;

- an effective antineoplastic amount of doxorubicin is from about 20 mg/m^2 to about 100 mg/m^2;

- an effective antineoplastic amount of epirubicin is from about 20 mg/m^2 to about 200 mg/m^2;

- an effective antineoplastic amount of idarubicin is from about 1 mg/m^2 to about 50 mg/m^2;

- an effective antineoplastic amount of mitoxantrone is from about 10 mg/m^2 to about 20 mg/m^2;

- an effective antineoplastic amount of paclitaxel is from about 100 mg/m^2 to about 300 mg/m^2;

- an effective antineoplastic amount of docetaxel is from about 50 mg/m^2 to about 100 mg/m^2;

- an effective antineoplastic amount of vinorelbine is from about 15 mg/m^2 to about 30 mg/m^2;

- an effective antineoplastic amount of cyclophosphamide is from about 100 mg/m^2 to about 1500 mg/m^2;

- an effective antineoplastic amount of melphalan is from about 1 mg/m^2 to about 10 mg/m^2;

- an effective antineoplastic amount of 5-fluorouracil is from about 100 mg/m^2 to about 1000 mg/m^2;

- an effective antineoplastic amount of capecitabine is from about 10 mg/m^2 to about 1000 mg/m^2;

- an effective antineoplastic amount of methotrexate is from about 10 mg/m^2 to about 1000 mg/m^2;

- an effective antineoplastic amount of topotecan is from about 1 mg/m^2 to about 5 mg/m^2;

- an effective antineoplastic amount of irinotecan is from about 50 mg/m^2 to about 350 mg/m^2;

and an effective amount of aromatase inhibitor is from about 0.5 to about 500 mg.

32. (Previously presented) The pharmaceutical composition according to claim 31, wherein when administered orally, the amount of aromatase inhibitor exemestane is from about 5 to about 200 mg, the amount of fadrozole is from about 0.5 to about 10 mg, the amount of letrozole from about 0.5 to about 10 mg, and the amount of anastrozole is from about 0.5 to about 10 mg.

33. (Previously presented) The pharmaceutical composition according to claim 31, wherein when administered parenterally, the amount of aromatase inhibitor exemestane is from about 50 to about 500 mg, and the amount of formestane is from about 250 to about 500 mg.

34. (Currently amended) A pharmaceutical product comprising an antineoplastic agent and an aromatase inhibitor, wherein said agent and said inhibitor are present in amounts effective to produce a superadditive antitumor effect, ~~and wherein the aromatase inhibitor is not aminogluthetimide when the antineoplastic agent is a combination consisting of cyclophosphamide, doxorubicin and 5-fluorouracyl, and~~ wherein said pharmaceutical product is capable of separate, simultaneous or sequential administration in breast cancer therapy in humans, and wherein the antineoplastic agent is selected from the group consisting of doxorubicin, epirubicin, idarubicin, nemorubicin, mitoxantrone, losoxantrone, etoposide, teniposide, paclitaxel, docetaxel, vinblastine, vinorelbine, cyclophosphamide, ifosfamide, melphalan, 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulfonyldaunorubicin, fluorouracil, capecitabine, gemcitabine, methotrexate, edatrexate, topotecan, irinotecan, 9-nitrocamptothecin

and a polymeric derivative of camptothecin designated PNU 166148, and the aromatase inhibitor is selected from the group consisting of exemestane, formestane, fadrozole, vorozole, letrozole, anastrozole and 4-[(4-bromobenzyl)(4-cyanophenyl)amino]-4H-1,2,4-triazole.

35. (Currently amended) A method for treating breast cancer in humans, said method comprising administering an antineoplastic agent to a human in need thereof and administering an aromatase inhibitor, in amounts effective to produce a superadditive antitumor effect, ~~wherein the aromatase inhibitor is not aminogluthetimide when the antineoplastic agent is a combination consisting of cyclophosphamide, doxorubicin and 5-fluorouracyl~~, wherein the antineoplastic agent is selected from the group consisting of doxorubicin, epirubicin, idarubicin, nemorubicin, mitoxantrone, losoxantrone, etoposide, teniposide, paclitaxel, docetaxel, vinblastine, vinorelbine, cyclophosphamide, ifosfamide, melphalan, 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulfonyldaunorubicin, fluorouracil, capecitabine, gemcitabine, methotrexate, edatrexate, topotecan, irinotecan, 9-nitrocamptothecin and a polymeric derivative of camptothecin designated PNU 166148, and the aromatase inhibitor is selected from the group consisting of exemestane, formestane, fadrozole, vorozole, letrozole, anastrozole and 4-[(4-bromobenzyl)(4-cyanophenyl)amino]-4H-1,2,4-triazole.

36. (Currently amended) A method for treating breast cancer in humans, said method comprising administering to a human in need thereof (a) an antineoplastic agent and (b) an aromatase inhibitor, wherein said agent and said inhibitor are administered in amounts effective to produce a superadditive antitumor ~~erect~~ effect, ~~and the aromatase inhibitor is not aminogluthetimide when the antineoplastic agent is a combination consisting of cyclophosphamide, doxorubicin and 5-fluorouracyl~~, and wherein the antineoplastic agent is

selected from the group consisting of doxorubicin, epirubicin, idarubicin, nemorubicin, mitoxantrone, losoxantrone, etoposide, teniposide, paclitaxel, docetaxel, vinblastine, vinorelbine, cyclophosphamide, ifosfamide, melphalan, 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulfonyldaunorubicin, fluorouracil, capecitabine, gemcitabine, methotrexate, edatrexate, topotecan, irinotecan, 9-nitrocamptothecin and a polymeric derivative of camptothecin designated PNU 166148, and the aromatase inhibitor is selected from the group consisting of exemestane, formestane, fadrozole, vorozole, letrozole, anastrozole and 4-[(4-bromobenzyl)(4-cyanophenyl)amino]-4H-1,2,4-triazole.

37. (Currently canceled).

38. (Currently canceled).

39. (Currently canceled).

40. (Currently amended) The method according to claim ~~38~~ 36, wherein 1, 2 or 3 antineoplastic agents is selected from the group consisting of epirubicin, doxorubicin, idarubicin, paclitaxel, docetaxel, 5-fluorouracil, cyclophosphamide and vinorelbine, and 1 or 2 steroidal aromatase inhibitors is selected from the group consisting of exemestane, formestane, anastrozole, letrozole and fadrozole, are administered.

41. (Currently canceled).

42. (Currently amended) The method according to claim ~~41~~ 36, wherein one or two antineoplastic agents is selected from the group consisting of epirubicin and docetaxel, and the steroidal aromatase inhibitor is exemestane, are administered.

43. (Currently amended) The method according to claim ~~39~~ 36, wherein:

- an effective antineoplastic amount of vinblastine is from about 3 mg/m^2 to about 10 mg/m^2;

- an effective antineoplastic amount of doxorubicin is from about 20 mg/m^2 to about 100 mg/m^2;

- an effective antineoplastic amount of epirubicin is from about 20 mg/m^2 to about 200 mg/m^2;

- an effective antineoplastic amount of idarubicin is from about 1 mg/m^2 to about 50 mg/m^2;

- an effective antineoplastic amount of mitoxantrone is from about 10 mg/m^2 to about 20 mg/m^2;

- an effective antineoplastic amount of paclitaxel is from about 100 mg/m^2 to about 300 mg/m^2;

- an effective antineoplastic amount of docetaxel is from about 50 mg/m^2 to about 100 mg/m^2;

- an effective antineoplastic amount of vinorelbine is from about 15 mg/m^2 to about 30 mg/m^2;

- an effective antineoplastic amount of cyclophosphamide is from about 100 mg/m^2 to about 1500 mg/m^2;

- an effective antineoplastic amount of melphalan is from about 1 mg/m^2 to about 10 mg/m^2;

- an effective antineoplastic amount of 5-fluorouracil is from about 100 mg/m^2 to about 1000 mg/m^2;

- an effective antineoplastic amount of capecitabine is from about 10 mg/m^2 to about 1000 mg/m^2;

- an effective antineoplastic amount of methotrexate is from about 10 mg/m^2 to about 1000 mg/m^2;

- an effective antineoplastic amount of topotecan is from about 1 mg/m^2 to about 5 mg/m^2;

- an effective antineoplastic amount of irinotecan is from about 50 mg/m^2 to about 350 mg/m^2;

and an effective amount of aromatase inhibitor is from about 0.5 to about 500 mg.

44. (Currently canceled)

45. (Currently canceled)

46. (Currently amended) A method for lowering the side effects in humans caused by breast cancer therapy with an antineoplastic agent, said method comprising administering to a human in need thereof a pharmaceutical composition comprising (a) an antineoplastic agent and (b) an aromatase inhibitor, wherein said agent and said inhibitor is present in a quantity to produce a superadditive antitumor effect, ~~and the aromatase inhibitor is not aminogluthetimide when the antineoplastic agent is a combination consisting of a cyclophosphamide, doxorubicin and 5-fluorouracyl~~, and wherein the antineoplastic agent is selected from the group consisting of doxorubicin, epirubicin, idarubicin, nemorubicin, mitoxantrone, losoxantrone, etoposide,

teniposide, paclitaxel, docetaxel, vinblastine, vinorelbine, cyclophosphamide, ifosfamide, melphalan, 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulfonyldaunorubicin, fluorouracil, capecitabine, gemcitabine, methotrexate, edatrexate, topotecan, irinotecan, 9-nitrocamptothecin and a polymeric derivative of camptothecin designated PNU 166148, and the aromatase inhibitor is selected from the group consisting of exemestane, formestane, fadrozole, vorozole, letrozole, anastrozole and 4-[(4-bromobenzyl)(4-cyanophenyl)amino]-4H-1,2,4-triazole.

47. (Currently amended) The method according to claim ~~40~~ 36, wherein:

- an effective antineoplastic amount of vinblastine is from about 3 mg/m^2 to about 10 mg/m^2;

- an effective antineoplastic amount of doxorubicin is from about 20 mg/m^2 to about 100 mg/m^2;

- an effective antineoplastic amount of epirubicin is from about 20 mg/m^2 to about 200 mg/m^2;

- an effective antineoplastic amount of idarubicin is from about 1 mg/m^2 to about 50 mg/m^2;

an effective antineoplastic amount of mitoxantrone is from about 10 mg/m^2 to about 20 mg/m^2;

- an effective antineoplastic amount of paclitaxel is from about 100 mg/m^2 to about 300 mg/m^2;

- an effective antineoplastic amount of docetaxel is from about 50 mg/m^2 to about 100 mg/m^2;

- an effective antineoplastic amount of vinorelbine is from about 15 mg/m^2 to about 30 mg/m^2;

- an effective antineoplastic amount of cyclophosphamide is from about 100 mg/m^2 to about 1500 mg/m^2;

- an effective antineoplastic amount of melphalan is from about 1 mg/m^2 to about 10 mg/m^2;

- an effective antineoplastic amount of 5-fluorouracil is from about 100 mg/m^2 to about 1000 mg/m^2;

- an effective antineoplastic amount of capecitabine is from about 10 mg/m^2 to about 1000 mg/m^2;

- an effective antineoplastic amount of methotrexate is from about 10 mg/m^2 to about 1000 mg/m^2;

- an effective antineoplastic amount of topotecan is from about 1 mg/m^2 to about 5 mg/m^2;

- an effective antineoplastic amount of irinotecan is from about 50 mg/m^2 to about 350 mg/m^2;

and an effective amount of aromatase inhibitor is from about 0.5 to about 500 mg.

48. (New) The method according to claim 36, wherein one or two antineoplastic agents are administered, the one or two antineoplastic agents and the steroidal aromatase inhibitors are administered orally, and the aromatase inhibitor is selected from the group consisting of from about 5 to about 200 mg of exemestane, from about 0.5 to about 10 mg fadrazole, from about 0.5 to about 10 mg letrozole, and from about 0.5 to about 10 mg anastrozole.

49. (New) The method according to claim 36, wherein one or two antineoplastic agents are administered, the one or two antineoplastic agents and the steroidal aromatase inhibitors are

administered parenterally, and the aromatase inhibitor is selected from the group consisting of from about 5 to about 500 mg exemestane, and from about 250 to about 500 mg formestane.